CorMedix (CRMD) investor relations material

Company transformation and strategic direction

• Transitioned from a single-asset company with a broken supply chain to a diversified portfolio with institutional care assets and a $700 million enterprise value.

• Acquired Melinta for $300 million upfront, diversifying into anti-infectives and expanding into new therapeutic areas beyond renal.

• Focused on institutional settings such as hospitals and infusion clinics, with a pipeline including REZZAYO and DefenCath.

• Maintains strong cash position and seeks additional synergistic acquisitions.

Product portfolio and pipeline updates

• Melinta portfolio includes injectable anti-infectives with over $130 million in trailing revenue; REZZAYO shows strong growth potential.

• REZZAYO, a long-acting echinocandin, met primary non-inferiority endpoint in phase III for prophylaxis of invasive fungal infections, with favorable safety data.

• DefenCath, a catheter lock solution, delivered strong Q1 sales but faces price erosion post-TDAPA; guidance for 2027 anticipates higher selling prices.

• Pipeline includes DefenCath for parenteral nutrition (study completion targeted for 2028), and a minority stake in Talphera with rights to acquire upon positive phase III results.

Reimbursement landscape and market positioning

• DefenCath's reimbursement transitions from buy-and-bill to bundled payments, with significant price erosion expected in late 2024.

• Medicare Advantage, covering nearly half of ESRD patients, is a key future value driver; efforts underway to secure separate payment for DefenCath.

• Legislative developments, such as the Kidney Care Access Protection Act, could transform reimbursement for innovative ESRD drugs.